Anbio Biotechnology (NASDAQ:NNNN – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Tuesday. The stock traded as low as $4.05 and last traded at $4.38, with a volume of 6,417 shares. The stock had previously closed at $4.41.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings upgraded Anbio Biotechnology from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, October 8th. One investment analyst has rated the stock with a Hold rating. According to data from MarketBeat.com, the company has an average rating of “Hold”.
View Our Latest Research Report on Anbio Biotechnology
Anbio Biotechnology Stock Performance
About Anbio Biotechnology
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.
Further Reading
- Five stocks we like better than Anbio Biotechnology
- UnitedHealth Beats on Earnings, But Investors Question Growth Path
- Swarm Economics: Can XTEND AI Robotics Deliver at Scale?
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
Receive News & Ratings for Anbio Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anbio Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
